How This Historic FDA Approval Benefits Viatris

·4-min read
How This Historic FDA Approval Benefits Viatris

U.S. biopharmaceutical company Viatris (NASDAQ: VTRS) and its partner, Indian biopharma Biocon, announced on July 28 that the U.S. Food and Drug Administration (FDA) had approved their biosimilar insulin drug, Semglee, as an "interchangeable biosimilar" -- a direct alternative to Sanofi's (NASDAQ: SNY) blockbuster insulin drug, Lantus. Semglee is the first interchangeable biosimilar insulin product approved by the FDA.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting